Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.
Acadia Pharma's attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer's disease-related psychosis have suffered another major setback.
Acadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Nuplazid (pimavanserin) for use in dementia-related psychosis (DRP) – with the c
Feedback is being sought on a proposed pathway that aims to accelerate access to new medical technologies by laying out a common set of rules and commissioning principles.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.